The Tesamorelin + Ipamorelin blend is the benchmark GH axis dual-stimulation research combination, pairing the only FDA-approved GHRH analogue (Tesamorelin, approved as Egrifta for HIV-associated lipodystrophy) with the GHS-R1a agonist most selective for pure GH secretion (Ipamorelin — minimal cortisol or prolactin elevation vs other secretagogues).
The mechanistic synergy: Tesamorelin acts on the pituitary GHRH receptor (GHRHR) to increase GH pulse amplitude. Ipamorelin acts on the ghrelin receptor (GHS-R1a) — a completely independent pathway — to trigger additional GH release. Two pathways → two inputs → superior combined GH axis stimulation. This combination is a standard in GH axis research protocols studying pulsatile GH biology.
The Tesamorelin + Ipamorelin blend combines two complementary GH axis stimulators: Tesamorelin (a GHRH analogue that stimulates pituitary GHRH receptors to increase GH pulse amplitude) and Ipamorelin (a GHS-R1a agonist that stimulates GH release via the ghrelin receptor, independently of GHRH). Together they activate two distinct pathways simultaneously, producing synergistic GH secretion superior to either alone.
Why research Tesamorelin and Ipamorelin together?
The GHRH + GHS-R1a combination is mechanistically synergistic: GHRH increases the amplitude of GH pulses (how much GH is released each time); GHS-R1a agonists like Ipamorelin increase frequency and trigger release independently. Together they saturate both pathways, producing maximal GH axis stimulation without relying on a single mechanism. This combination is widely studied in GH axis research and has been used in FDA-approved Tesamorelin research (GHRH analogue approved for HIV-associated lipodystrophy).
What is Tesamorelin?
Tesamorelin (TH9507) is a synthetic GHRH analogue — a modified form of human GHRH(1-44) with a trans-3-hexenoic acid group stabilising the N-terminus. It was FDA approved (Egrifta) for HIV-associated lipodystrophy, demonstrating significant visceral fat reduction (15–20%) in Phase 3 trials via GH axis stimulation. QSC stocks research-grade Tesamorelin for in vitro laboratory research.
Where can I buy this research blend?
QSC stocks Tesamorelin, Ipamorelin, and the Tesamorelin + Ipamorelin blend combination at ≥99% HPLC purity with Janoshik COA. Ships US Domestic 2–4 business days. Research use only.
Buy Research-Grade Tesamorelin + Ipamorelin Blend
≥99% HPLC · Janoshik COA · US Domestic 2–4 Days · Research Use Only
Research Use Only: Tesamorelin + Ipamorelin Blend is sold by QSC strictly for in vitro laboratory research. Not for human or veterinary use. Not FDA approved for clinical application.
